cyrilzakka/clinical-trials huggingface dataset:
Identification of Viruses Associated With Diseases of Unknown Cause

This study will try to identify new or known viruses responsible for diseases or conditions of unknown cause. Viruses are an important cause of illness. They have been identified as causes of several cancers, including certain liver cancers and cervical cancer. Several diseases, such as Kawasaki s disease, aplastic anemia, aphthous ulcers, and certain fevers of unknown origin in immune suppressed patients are thought possibly to be due to viruses, but their cause has not yet been determined. This study will use very sensitive molecular techniques to try to identify new or known viruses in patients with conditions of unknown causes. This study does not involve any treatment.

Any patient with a condition or disease whose cause is unknown may be eligible for this study. A referral from a local physician is required for patients who wish to enroll in this study.

Participants will have blood samples drawn up to four times during the study. The total amount of blood drawn in any 6-week period will not exceed 50 milliliters (about 3-1/2 tablespoons) for adults and 5 ml (about 1/2 tablespoon) per kilogram (2.2 pounds) for children. In addition, body fluids, such as joint or spinal fluid, or tissue samples, such as biopsy specimens, obtained previously for medical purposes, may be obtained for testing.

The patient s doctor will be informed of any positive findings from the samples. Identification of a virus does not necessarily mean that the virus is causing the patient s condition or disease. Additional tests from many patients with similar diseases or conditions are required before a virus can be definitively associated with a disease. Similarly, failure to find a virus does not necessarily mean that the patient is not infected with a virus that is causing the condition, as the tests used in this study are imperfect and will not detect certain forms of viruses that can cause disease.

Viral infections are an important cause of morbidity and mortality in hospitalized patients. Viruses have also been identified as the probable cause of a number of malignancies including hepatocellular carcinoma and cervical carcinoma. The purpose of this study is to identify novel viruses (or known viruses) that are associated with diseases whose etiology is unknown. Blood samples, body fluids, or discarded tissues (e.g. previous biopsy or autopsy material) saliva swabs, nasopharyngeal swabs, skin biopsies, or mucosal biopsies will be obtained from patients with clinical syndromes or diseases whose etiology is unknown. Highly sensitive assays using the polymerase chain reaction will be performed to attempt to identify novel or known viruses that might be present in the blood, body fluids, or tissues. Knowledge gained from this study could provide important insights into the cause of diseases whose etiology is presently unknown.

Eligibility Criteria:
* INCLUSION CRITERIA:

Any patient with a condition or disease whose etiology is unknown.

Adequate venous access.

EXCLUSION CRITERIA:

None
Chatbot Intervention for Anxiety and Depressive Symptoms in Young Adults

This clinical trial compares the effects of using an artificial intelligence based therapy chatbot and a self-help book to lower anxiety and depressive symptoms. The therapy chatbot (named Fido) is an application delivering support for mental health via a conversation-like interface in a highly inflected language (Polish).

The team will recruit young people (aged 18-35) who currently struggle with anxiety and/or depression. The participants will use the chatbot or self-help materials for two weeks. Then, the researchers will check if using the chatbot or the book improved several aspects of mental health and the quality of life. Moreover, they will compare the groups for any differences in outcomes.

The primary objective of this randomized controlled trial is to evaluate the effectiveness of a chatbot-delivered cognitive-behavioural intervention on anxiety and depressive symptoms (and their correlates, such as quality of life or feelings of loneliness) in a subclinical sample of about 80 participants.

The intervention results are compared to an active control intervention with popular self-help materials. Secondary objectives include the assessment and analysis of the human-chatbot therapeutic bond and general user experience.

The study uses a 2 x 3 mixed factorial design with two intervention arms (Fido chatbot vs self-help book) and three time points (T1: just prior to the intervention, T2: immediately after the intervention, T3: at a follow-up one month after the previous measurement). The primary intervention lasts two weeks.

All primary and secondary outcomes are assessed using self-administered online questionnaires in Polish. Each primary outcome measure is analyzed using a 2 (arms) x 2 (time points) ANOVA models with T1-T2 comparisons to test for the intervention effect and T1-T3 comparisons to check the stability of the intervention effect. Additional analyzes utilize standard NHST calculations and procedures (such as t-tests and correlation coefficients) alongside the conventional ⍺=.05 level.

Similarly to the previous research in this area, no blinding is used. Participants are informed about different conditions, but the research hypotheses are masked.

Eligibility Criteria:
Inclusion Criteria:

* declaring at least mild depressive or anxiety symptoms by achieving a total score of at least 16 points on Center for Epidemiologic Studies Depression Scale Revised or at least 50 points on Penn State Worry Questionnaire
* being able to visit the study site in Poznań (Poland) to complete all measurements

Exclusion Criteria:

* undergoing psychotherapy, coaching or psychopharmacological treatment
* being diagnosed with a neurological disorder
Efficiency of GDS Method for Lumbar Stabilization for Non-Specific Low Back Pain in Primary Care

The purpose of this randomized controlled trial was to assess the effectiveness of GDS Treatment Method for patients with subacute or chronic non-specific low back pain in Primary Care of Spanish National Health Service.

Low back pain is one of the most frequent ailments in industrialized countries, with a lifetime prevalence of more than 70%. It is responsible for a major portion of work absenteeism and is actually among those conditions which generate the greatest expense due to health and labor costs.

The Spanish National Health Service is a universal and free health care system. Non-specific low back pain (LBP) is a prevalent disorder, generating large health and social costs.

There is considerable variation in LBP related clinical practice and a considerable number of clinical guidelines have been developed for the management of subacute and chronic LBP patients.

Experience in Primary Care Centers of Madrid shows that physiotherapeutic intervention based on GDS Method for Articular and Muscular Chains is an efficient technique in the treatment of patients with diagnosis of non-specific low back pain compared with conventional physiotherapy treatment in Primary Care based on electrotherapy (TENS and microwave)

Currently, no randomized studies examining the effects of this method for patients with subacute or chronic non-specific low back pain have been published.

Eligibility Criteria:
Inclusion Criteria:

Participants were required to:

* Be aged 18 years or older;
* Have been diagnosed with simple mechanical LBP by their doctor and prescribed physiotherapy;
* Have an impairment secondary to functional overload and/or poor postural habits (patients with certain occupations were excluded if these could act as confounding factors);
* Not be receiving any other form of treatment;
* Not be neurologically compromised; and
* To be in a subacute or chronic stage of LBP exceeding 4 weeks.

Exclusion Criteria:

Subjects were excluded if they:

* Showed clear symptoms of depression;
* Refused to participate;
* Did not sign the informed consent form;
* Had any cognitive impairment that would prevent them from following instructions;
* Were unable to understand Spanish sufficiently to adequately follow instructions;
* Had the intention of moving from the area;
* Had any form of contraindication to the physiotherapeutic techniques to be applied to both groups;
* Had red flags, or warning signs, of serious illness such as cancer, infection, fracture or cauda equinal syndrome;
* Had yellow flags, or risk factors, for a psychological disorder or had lumbar pain whose main cause was not mechanical.
Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy

The purpose of this study is to evaluate the efficacy of ubiquinone and combined antioxidant therapy on progression, clinical regression, oxidative stress markers and mitochondrial dysfunction in non-proliferative diabetic retinopathy.

The investigators are interested in demonstrating the efficacy of Ubiquinone and combined antioxidant therapy in the pharmacological management of diabetic retinopathy since early stages.

Eligibility Criteria:
Inclusion Criteria:

* Patients with type 2 diabetes mellitus
* Patients with non proliferative diabetic retinopathy
* Glycated hemoglobin \< 12.0%
* Signing of informed consent

Exclusion Criteria:

* Patients with clinically significant macular edema
* Patients with diabetic retinopathy advanced lesions that have required or require specific treatment (laser, vitrectomy)
* Pretreatment with argon laser or excimer laser Ophthalmology surgery
* Any other associated ocular pathology (glaucoma, cataracts, changing cornea dystrophy, macular degeneration)
* Pregnancy, lactation, inadequate use of contraception
* Antioxidant drug and/or supplements six months previous to enrollment
* Renal and/or hepatic failure
* Age under 30 or over 75 years
* Severe cardiovascular disease (myocardial infarction, stroke, severe peripheral vasculopathy)
* Blood dyscrasias
* Have or have had cancer or other serious illness
* Neurodegenerative process
* Allergy to vitamins
ContraBand™: FIH Safety & Feasibility Study (RM-20-01)

The ContraBand™ device is intended for treatment of heart failure patients who remain symptomatic despite the use of optimally tolerated guideline directed medical therapy. ContraBand™ is a transcatheter constriction device which is implanted in the left and right branch pulmonary arteries, causing a local reduction in the internal diameters of these arteries, and resulting in an elevation in systolic right ventricular pressure. This may result in repositioning the interventricular septum to a more normal anatomical position, and supporting it with a "counter-pressure" during systole of the left ventricle. This study is a first-in-human, early feasibility, multi center, prospective, interventional, open-label, single-arm study.


Eligibility Criteria:
Inclusion Criteria:

1. Age is 18 - 85 years old
2. Chronic (\> 3 months) systolic heart failure
3. Symptomatic left heart failure Stage C (NYHA II\*-IVa)
4. LVEF 20 - 40%
5. Patients on optimal tolerated medical therapy for at least one month. If subject is on device therapy, if ICD for at least 1 month, if CRT/pacemaker, for at least 3 months.
6. Provide a personally signed and dated inform consent form, and able and willing to complete all qualifying diagnostic and functional tests and agrees to comply with study follow-up schedule.

Exclusion Criteria (selected):

1. Serum NT-proBNP \<300
2. Significant RV dysfunction with TAPSE \<17
3. Pulmonary Hypertension (sPAP \> 45 mmHg by Echo or mPAP \> 20 mmHg by RHC)
4. Anatomical pathology or constraints preventing appropriate access/implant of ContraBand™
5. Restrictive Cardiomyopathy or myocarditis
6. Patients with congenital heart disease and/or mechanical heart valve(s)
7. Any severe valve disease (Grade 3-4) and/or tricuspid regurgitation ≥ 2+ (in a scale of 5)
8. Hemodynamic instability: Hypotension (systolic pressure \<90 mmHg) or requirement for inotropic support or mechanical hemodynamic support
9. Active bacterial endocarditis or previous history of SBE (Subacute bacterial endocarditis)
10. Any planned cardiac surgery or interventions within the next six (6) months
11. Need for coronary artery revascularization
12. Myocardial infarction or any percutaneous cardiovascular intervention within 1 month
13. Cardiovascular surgery, or carotid surgery within 3 months
14. Acute kidney insufficiency and/or end stage renal disease requiring chronic dialysis (eGFR \< 30)

18. Leukopenia (WBC \< 4000 cells/μL), anemia (Hgb \< 9 g/dL), thrombocytopenia (platelets \< 150,000 cells/μL) or any known blood clotting disorder
Demineralized Dentin Graft in Preservation of Post-Extraction Sites Associated With Delayed Implant Placement

Thirty patients will be selected from outpatient clinic of the Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Mansoura University seeking for extraction of non-restorable mandibular posterior teeth For the 1st group: the socket will be grafted with completely demineralized dentin graft after 3 days of extraction, followed by delayed implant placement after 4 months.

For the 2nd group: the socket will be grafted with partially demineralized dentin graft in in the same day of extraction, followed by delayed implant placement after 4 months.


Eligibility Criteria:
Inclusion Criteria:

* Patient medically free from systemic diseases.
* Patient with good oral hygiene.
* Age above 18 years.
* Presence of non-restorable mandibular premolar tooth due to caries, root resorption, roots fracture, etc.
* No acute infection is present.
* No history of bruxism.
* Patients prepared to comply with the follow-up and maintenance program.

Exclusion Criteria:

* Patients with systemic diseases that interfere with dental implant insertion.
* Pregnancy.
* Immunocompromised patients.
* Existence of non-treated generalized progressive periodontitis.
Effectiveness of a Treatment With the Robot - Assisted Gait Training System Walkbot in Patients With Cerebral Palsy

The improvement of walking capacity is a key objective of the rehabilitation of children with PC. There are different approaches from physiotherapy to address this need, including walking on the ground and on treadmill with partial weight support. Currently, there are robotic technologies adapted to the functional rehabilitation of patients. Assisted gait training with robotic devices such as the Walkbot allows a longer duration of training, at more variable speeds, and with a constant gait pattern adapted to the patient. This training, based on the intensity and repetition of the movement, has beneficial effects on the recovery and improvement of the patient's postural and locomotor functions.

There are some studies that evaluate walking interventions on treadmill with partial weight support, on the ground and in assisted walking robot in patients with PC.

Currently, there are no studies conducted that report the effectiveness of interventions performed with robotic walking training device Walkbot K on PC. However, studies in adults with Walkbot S, affected with neurological injury, have reported good results.

Assisted gait training with robotic devices such as the Walkbot, based on the intensity and repetition of the movement, has beneficial effects on the recovery and improvement of the patient's postural and locomotor functions. However, due to the little evidence that exists, it is necessary to know the effectiveness of the Walkbot assisted walking robot in these patients by means of a clinical trial that allows to firmly establish the scope of its benefits.


Eligibility Criteria:
Inclusion Criteria:

* Cerebral palsy diagnosis (diplegia or tetraplegia)
* Ability to communicate even if not verbal (yes/not; gestures; pictograms; sounds)
* Levels II, III and IV in GMFCS
* Unsupported seating capacity
* Go on standing with or without help
* Not receiving therapy with a walking robot and not having received it in at least one year

Exclusion Criteria:

* Serious psychiatric problems
* Serious heart problems
* Active tumors
* Severe joint degenerative problems
* Degenerative diseases of the nervous system
* Mitochondrial diseases
* Recent surgeries
* Unbound fractures
* Severe osteoporosis
* Uncontrolled seizures
* Open wounds in the lower half of the body
* Extreme fear of being placed in robotic devices
* Anthropomorphic measures are below the minimum required to use the device
Cytomegalovirus Infection in Patients With HIV-1 Infection

The purpose of this study is to assess the level of CD4 and CD8 T cell activation in an observational cohort study of HIV-1 patients, virosuppressed on combined antiretroviral therapy (\< 50 copies/ml) for at least 2 years and to focus on two factors that could participate in this activation: cytomegalovirus infection and auto-immune disorders.

T cell activation plays a central role in HIV pathogenesis and is highly correlated to disease progression even in HIV patients virosuppressed on combined antiretroviral therapy since years. The mechanisms underlying this activation in virosuppressed patients are poorly understood. Identifying some factors involved in immune activation that can be targeted by therapies could optimize the treatment of HIV patients. The purpose of this study is to assess the level of CD4 and CD8 T cell activation in an observational cohort study of HIV-1 patients, virosuppressed on combined antiretroviral therapy (\< 50 copies/ml) for at least 2 years and to focus on two factors that could participate in this activation: cytomégalovirus infection and auto-immune disorders.

Eligibility Criteria:
Inclusion Criteria:

* Patients included in the Aquitaine ANRS CO3 cohort aged 18 years or older (confirmed HIV-1 infection and at least one follow-up in the cohort),
* plasma HIV-1 RNA \<50 copies / ml for at least 24 months under a highly active antiretroviral combination (treatment comprising at least 3 antiretroviral drugs) modified or initiated between 2005 and 2008,
* Follow-up in one of the departments of Bordeaux University Hospital or Libourne Hospital,
* Free, informed and written consent, signed by the patient and the investigator (Consent of the Aquitaine CO3 Cohort and linked to this specific study).

Exclusion Criteria:

* Presence of 2 consecutive measurements of HIV RNA\> 50 copies / ml,
* History of immunotherapy treatments (interleukin-2),
* Hepatitis B or C co-infections,
* Pregnancy
* Breastfeeding
* Symptomatic infectious episode in progress.
Leader - Evaluation of Endotak Reliance

The objective of this study is to demonstrate the efficacy of the ENDOTAK® RELIANCE™ defibrillation leads connected to a defibrillator or a cardiac resynchronization defibrillator from implant until 12 months.

Baseline and clinical data were collected at inclusion, as were data on procedural characteristics, device implantation-related adverse events and device programming at the time of hospital discharge. Patients were subsequently divided in two groups: patients who underwent VF induction at implantation or before hospital discharge(VF induction group); and patients who did not undergo VF induction (untested group).The patients were followed up at 3-6 months and at12 months after the implantation. VF induction procedures were left to the investigator's discretion, but reasons for not performing a VF induction at implantation were recorded prospectively. ICD programming parameters for tachycardia or bradycardia were also left at the investigator's discretion.

Eligibility Criteria:
Inclusion Criteria:

* ICD indication according to current guidelines with or without cardiac resynchronization therapy, being implanted with a Guidant ENDOTAK RELIANCE defibrillation lead as first implant, age above 18 years, able to understand the nature of the study and to be available for all follow-ups, having given consent in writing for anonymous data collection, life expectancy \> 1 year.

Exclusion Criteria:

* device replacement without concomitant implant of a Reliance defibrillation lead, pregnancy or of birth bearing age without contraception, participation in another clinical study, short life expectancy due to other medical conditions, not willing to sign the consent form, geographically unstable for a defibrillator follow-up as required per protocol, having a ventricular arrhythmia, that can be treated by drugs or surgery
Autologous Neo-Bladder Construct in Non-Neurogenic Overactive Bladder and Urge Predominant Incontinence

Subjects with non-neurogenic over-active bladder will be enrolled. The hypothesis is that augmentation cystoplasty using an autologous neo-bladder construct will increase functional capacity and thereby reduce the number of micturition episodes per day in subjects with non-neurogenic over active bladder and urge predominant incontinence.

Subjects with non-neurogenic over-active bladder and urge predominant incontinence who are intolerant to medical therapy or have persistence of symptoms despite medical therapy and require augmentation cystoplasty will be enrolled. The hypothesis is that augmentation cystoplasty using an autologous neo-bladder construct will increase functional capacity and thereby reduce the number of micturition episodes per day in subjects with non-neurogenic over active bladder and urge predominant incontinence.

Eligibility Criteria:
Inclusion Criteria:

* History of non-neurogenic overactive bladder for at least 12 months prior to study entry
* Intolerance to medical therapy or persistence of symptoms despite medical therapy

Exclusion Criteria:

* Subjects with stress incontinence or mixed incontinence where the predominant component is stress incontinence
* Use of Botulinum Toxin A injections into the bladder within the previous 6 months
* Presence of a neuromodulator
* Using catheterization as a way to control incontinence
* History of bladder cancer
Effects of Early Manual Therapy on Functional Outcomes After Volar Plating of Distal Radius Fractures

The aim of the study was to investigate the effects of early manual therapy on function, pain, range of motion (ROM), hand and pinch grip strength and disability level in patients underwent volar plating after distal radius fracture (DRF). Patients were randomly divided into two groups: Routin Physiotherapy (RP) or Early Manual Therapy (EMT). While RP group received routine physiotherapy, EMT group received routine physiotherapy plus Mulligan's Mobilization With Movement technique. All treatments were done two sessions a week, through 12 weeks. Function, pain, range of motion (ROM), hand and pinch grip strength and disability level of patients were assessed. Measurements were made at postoperative week 3, 6 and 12.


Eligibility Criteria:
Inclusion Criteria:

* An age of eighteen years or older
* An unstable fracture of the distal end of the radius
* Fixation with a volar locking plate
* Able to read, write, and understand Turkish
* Willing and able to attend the study

Exclusion Criteria:

* Previous fracture on the injured side
* Concurrent fracture in contralateral upper extremity
* Accompanied bony and soft tissue injuries other than radius fracture
* Inflammatory joint diseases, metabolic diseases and neurological diseases
* Mental and cognitive disorders that would seriously affect cooperation